Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors

The Oncologist(2025)10.1093/oncolo/oyaf169Source: DataRank Database

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors is a research paper published in The Oncologist (2025). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: goldTopics (27)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Farshid Dayyani ORCID,David Sommerhalder ORCID,Andrae Lavon Vandross,Meredith S. Pelster,Jason T. Henry ORCID

Live enrichment

PubMed:40580997 PMC:PMC12236304

California Institute for Regenerative Medicine

Grant: CLIN2-14232

National Cancer Institute

Grant: P30 CA016672

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

NIH HHS

Tachyon Therapeutics, Inc

University of Texas MD Anderson Cancer Center

goldLicense: cc-by-nc

publisherhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyaf169/63545774/oyaf169.pdf

publisherhttps://academic.oup.com/oncolo/article-pdf/30/7/oyaf169/63545774/oyaf169.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12236304

Europe_PMChttps://europepmc.org/articles/PMC12236304

Europe_PMChttps://europepmc.org/articles/PMC12236304?pdf=render

Fields of Study

Medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansNeoplasmsMaximum Tolerated DoseAdultAgedMiddle AgedFemaleMaleJumonji Domain-Containing Histone Demethylases

Keywords

EpigeneticHistone Lysine DemethylaseKdm4Tach101ZavondemstatMaleAdultJumonji Domain-Containing Histone DemethylasesMaximum Tolerated DoseNeoplasmsHumansFemaleNew Drug Development and Clinical PharmacologyMiddle AgedAged